Compare PubMatic Inc (PUBM) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PubMatic Inc vs Zoetis Inc — how do they compare? PubMatic Inc trades at $12.64 (market cap $600.05M), while Zoetis Inc trades at $74.04 (market cap $31.59B). The key difference: Zoetis Inc is far larger — about 52.6× PubMatic Inc's market cap, and Zoetis Inc pays a 2.81% dividend while PubMatic Inc pays none. Which is the better fit depends on your goals.
| PUBM | ZTS | |
|---|---|---|
Market Cap | $600.05M | $31.59B |
Sector | Technology | Health |
52-Week High | $13.83 | $156.76 |
52-Week Low | $6.28 | $71.91 |
Enterprise Value | $497.55M | $38.89B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PubMatic trades at $12.92, up 1.49% today, with a neutral technical signal and bullish moving averages. The company reported Q1 2026 revenue that beat expectations despite a net loss, and maintains a strong gross margin of 63.22%. Recent news highlights product launches like AgenticOS and partnerships expanding its programmatic advertising reach, with Q2 2026 results due August 6, 2026.
Outlook is mixed: analyst consensus is split evenly between Buy and Hold with a $17.00 price target, suggesting 32% upside, but risks include sustained negative net income margins and competitive pressures in ad tech. Cash flow remains positive, supporting operations amid profitability challenges.
Zoetis (ZTS) trades at $75.33, down 1.61% amid mixed technical signals and ongoing securities litigation. The stock shows strong fundamentals with a 28.03% net margin and 67.75% ROE, supported by consistent revenue growth from $8.1B in 2022 to $9.47B in 2025. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, with Q2 results pending. Analyst consensus remains positive with a $101.43 price target, though technical indicators show neutral momentum near key support at $75.
The outlook for ZTS is cautiously optimistic given robust profitability and analyst support, but significant legal overhangs and recent earnings volatility present near-term risks. Long-term growth in animal health markets offers upside, yet investors should monitor litigation developments and Q2 earnings for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
